Scholars Central

Research articlePublished 5 Feb 2018

Phase I Study of CIGB-300 Administered Intravenously in Patients with Relapsed/ Refractory Solid Tumors

Authors: Noyde Batista-Albuerne, Lidia González-Méndez, Idrian García-García, Eduardo Fernández- Sánchez, Robin García-Diegues, Ana de la Torre-Santos, Yenima Martín-Bauta, Ivette Raíces-Cruz, Carmen M Valenzuela-Silva, Vilcy Reyes-Nicolás, Yasser Perera-Negrín, Josué de la Torre-Pupo, Daniel F Alonso, Roberto Gómez, Boris E Acevedo-Castro, Verena L Muzio-González, Silvio E Perea-Rodríguez, Jorge L Soriano-García

Journal of Medical Oncology

Volume 1 · Issue 1 · Pages 4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: CIGB-300 is an anti-CK2 peptide previously tested by intralesional injections. Here, we explored tolerability, drug accumulation ratio and clinical benefit of intravenous CIGB-300 in patients with relapsed/refractory solid tumors. Methods: A multicenter and open-label phase I study. CIGB-300 administration was performed during 15 min once daily on days 1-5 in alternate weeks until completing three cycles. Stage 1 aimed to determine Maximum Tolerated Dose (MTD) and dose-limiting toxicity (DLT) in dose-escalation (0.2-1.6 mg/kg) while stage 2 explored drug accumulation ratio comparing Cmax and AUC0-12 from first and fifth infusions with 1.6 mg/kg of CIGB-300. Clinical benefit was assumed if patients lived ≥ 6 months. Results: In total, 16 patients were enrolled. Neither MTD nor DLT was observed. The most frequent adverse events were those related to mild allergic syndrome (61.6%) whose magnitude behaved dose-dependently. Drug accumulation ratio between infusions #1 and #5 was 1.0. Twelve patients (75%) lived >6 months and seven patients (43.7%) lived ≥ 12 months after CIGB-300 monotherapy. Four patients died before 6 months. Conclusion: Intravenous administration of CIGB-300 1.6 mg/kg is recommended to be tested in Phase 2-3 trials in patients with either relapsed/refractory NSCLC or breast cancer. Efficacy of once versus twice-daily CIGB-300 administrations can be also compared in upper phase trials.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Medical Oncology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Medical Oncology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Noyde Batista-Albuerne”
  • BylineArticles whose byline prints “Lidia González-Méndez”
  • BylineArticles whose byline prints “Idrian García-García”
  • BylineArticles whose byline prints “Eduardo Fernández- Sánchez”
  • BylineArticles whose byline prints “Robin García-Diegues”
  • BylineArticles whose byline prints “Ana de la Torre-Santos”
  • BylineArticles whose byline prints “Yenima Martín-Bauta”
  • BylineArticles whose byline prints “Ivette Raíces-Cruz”